Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 | P21728 | 1/20 | 0.39 |
| ▸ | DRD5 | P21918 | 1/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.37 |
| ▸ | CXCR3 | P49682 | 3/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.36 |
| ▸ | HTR6 | P50406 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.35 |
| ▸ | MAT2A | P31153 | 1/20 | 0.35 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4981265 | 0.80 | DRD1 (0.43) | DRD1DRD5HIF1ACNR1MAT2A | |
| SCHEMBL4520925 | 0.80 | DRD1 (0.37) | DRD1DRD5PDE10AHTR6CNR1 | |
| SCHEMBL4429967 | 0.80 | DRD1 (0.43) | DRD1DRD5HIF1ACNR1MAT2A | |
| SCHEMBL4429964 | 0.80 | DRD1 (0.43) | DRD1DRD5HIF1ACNR1MAT2A | |
| SCHEMBL4981916 | 0.79 | DRD1 (0.40) | DRD1DRD5PDE4BPDE4DHIF1A | |
| SCHEMBL4531198 | 0.78 | CNR1 (0.43) | DRD1DRD5HIF1ACNR1KDM4E | |
| SCHEMBL4514455 | 0.77 | CNR1 (0.39) | DRD1DRD5PDE4BPDE4DHIF1A | |
| SCHEMBL4521436 | 0.76 | FLT3 (0.39) | DRD1DRD5CNR1TSHR | |
| SCHEMBL1993198 | 0.73 | PDE4B (0.44) | PIK3CDPDE4BPDE4DHRH3SMN1; SMN2 | |
| SCHEMBL5437238 | 0.73 | PTGS2 (0.46) | HTR6KDM4ETSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2061470-A2 | HALOALKYL-SUBSTITUTED PYRIMIDINONE DERIVATIVES | Neurogen Corporation (US) | 2009-05-27 | — | — | EP | claimed |
| US-20080090845-A1 | Haloalkyl-substituted pyrimidinone derivatives | NEUROGEN CORPORATION (US) | 2008-04-17 | — | — | US | claimed |
| WO-2008024433-A2 | HALOALKYL-SUBSTITUTED PYRIMIDINONE DERIVATIVES | NEUROGEN CORPORATION (US) | 2008-02-28 | — | — | WO | claimed |
| US-20080090845-A1 | Haloalkyl-substituted pyrimidinone derivatives | NEUROGEN CORPORATION (US) | 2008-04-17 | — | — | US | disclosed |
| US-20080090845-A1 | Haloalkyl-substituted pyrimidinone derivatives | NEUROGEN CORPORATION (US) | 2008-04-17 | — | — | US | disclosed |
| US-20080090845-A1 | Haloalkyl-substituted pyrimidinone derivatives | NEUROGEN CORPORATION (US) | 2008-04-17 | — | — | US | disclosed |
| WO-2008024433-A2 | HALOALKYL-SUBSTITUTED PYRIMIDINONE DERIVATIVES | NEUROGEN CORPORATION (US) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090845-A1 | Haloalkyl-substituted pyrimidinone derivatives | PIGS, GPR174, GPR17 | DRD1 1261/4885DRD5 1056/4885PDE10A 1926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.